桃红四物汤通过逆转ACSL4介导的脂质蓄积并促进线粒体自噬改善硫代乙酰胺诱导的肝纤维化
桃红四物汤(THSWT)是临床用于妇科和慢性肝病的中药复方。该研究用UHPLC-MS/MS表征THSWT化学成分,小鼠每日口服THSWT 6周并给予硫代乙酰胺(TAA)造模,结合RNA测序、非靶向代谢组学和分子生物学实验探究机制。结果显示THSWT修复脂质代谢紊乱、阻断胶原蓄积,机制上通过阻断ACSL4并促进线粒体自噬逆转肝纤维化。
要点
- THSWT可修复TAA诱导的脂质代谢紊乱并阻断胶原蓄积。
- ACSL4是人和小鼠中通过破坏肝线粒体脂质氧化代谢的关键促纤维化靶点。
- THSWT通过阻断ACSL4并促进线粒体自噬发挥抗纤维化作用。
核心结论
- THSWT可能通过调节脂质代谢和促进肝脏线粒体自噬成为治疗肝纤维化及其并发症的潜在选择。
研究设计与样本
- 采用UHPLC-MS/MS探究THSWT的化学表征。
- 小鼠每日口服THSWT一次,持续6周,同时给予TAA刺激。
- 通过血清生物标志物和组织病理学染色反映肝功能。
- 应用RNA测序、非靶向代谢组学和分子生物学实验探究潜在机制。
主要发现
- THSWT在TAA刺激的小鼠和肝细胞中均深度修复脂质代谢功能障碍并阻断胶原蓄积。
- RNA测序和非靶向代谢组学结果显示,THSWT的抗纤维化作用主要依赖脂质代谢修复。
- THSWT增加乙酰辅酶A、磷脂酰胆碱、磷脂酰乙醇胺、溶血磷脂酰胆碱和溶血磷脂酰乙醇胺水平。
- THSWT降低酰基辅酶A、总胆固醇、二酰甘油、三酰甘油和磷脂酰肌醇的相对丰度。
- 长链酰基辅酶A合成酶4(ACSL4)在人和小鼠中均为关键促纤维化靶点,通过破坏肝线粒体脂质氧化和代谢发挥作用。
临床怎么用
- THSWT在临床应用于妇科和慢性肝病,该研究为其治疗肝纤维化提供了实验依据。
- ACSL4可作为肝纤维化治疗的潜在分子靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Liver fibrosis is a generic fibrous scarring event resulting from accumulation of extracellular matrix (ECM) proteins, easily progressing to end-stage liver diseases. Tao-Hong-Si-Wu-Tang (THSWT) is a traditional Chinese medicine formula applied in clinics to treat gynecological and chronic liver diseases. However, the role of THSWT on thioacetamide (TAA)-induced hepatic fibrosis and the specific mechanisms remains unclear. AIM OF THE STUDY: To investigate the improving effects of THSWT on TAA-insulted hepatic fibrosis and the underlying mechanisms. MATERIALS AND METHODS: UHPLC-MS/MS was performed to explore the chemical characterization of THSWT. Mice were orally administered with THSWT once daily for 6 weeks along with TAA challenge. Liver function was reflected through serum biomarkers and histopathological staining. RNA sequencing, non-targeted metabolomics and molecular biology experiments were applied to investigate the underlying mechanisms. RESULTS: THSWT profoundly repaired lipid metabolism dysfunction and blocked collagen accumulation both in TAA-stimulated mice and in hepatocytes. Results of RNA sequencing and non-targeted metabolomics revealed that the anti-fibrotic effects of THSWT mostly relied on lipid metabolism repairment by increasing levels of acetyl-CoA, phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine and lysophosphatidylethanolamine, and decreasing relative abundances of acyl-CoA, total cholesterol, diacylglycerol, triacylglycerol and phosphatidylinositol. Mechanically, long-chain acyl-CoA synthetases 4 (ACSL4) was a key profibrotic target both in human and mice by disrupting lipid oxidation and metabolism in hepatic mitochondria. THSWT effectively blocked ACSL4 and promoted mitophagy to reverse above outcomes, which was verified by mitophagy depletion. CONCLUSION: THSWT may be a promising therapeutic option for treating hepatic fibrosis and its complications by modulating lipid metabolism and promoting mitophagy in livers.
引用
- Wu J, Gong L, Li Y, et al. Tao-Hong-Si-Wu-Tang improves thioacetamide-induced liver fibrosis by reversing ACSL4-mediated lipid accumulation and promoting mitophagy. J Ethnopharmacol. 2024. PMID: 38878839. doi:10.1016/j.jep.2024.118456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。